02.07.2023 | Tracker

Top 50 Pharma Tracker: eHCPs approve of new pharma trial data at ASCO 2023

By Aman Jandu

Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.

The Top 50 Pharmaceutical Companies mentioned by eHCPs on Twitter

June RankMay RankCompany
Name
Total
Mentions
Account
Mentions
Account
Retweets
11Pfizer3,62234031
22Moderna1,327906
33Johnson & Johnson77524410
45AstraZeneca51727416
513Lilly5054244
64GSK45817845
717Merck & Co3181233
86Otsuka3172084
912Novo Nordisk3172405
108Roche30413717
11N/ABioNTech300130
129Gilead Sciences2851556
1215Bayer2857410
1410Sanofi21912520
157Abbott1951878
1623BMS1941474
1714Novartis1631078
18N/ANovavax14592
1916Takeda1391240
2018Boehringer Ingelheim99764
2138Organon8720
2211AbbVie85397
2319Amgen83534
2430Daiichi Sankyo80210
2528Biogen73260
2639Vertex67675
2721Regeneron65381
2829Eisai60231
2920Servier522812
3037Teva51465
3122Fresenius43111
3124UCB433720
3332Merck KGaA343211
3436Ipsen28220
3525Astellas27210
3631Viatris2400
3733CSL21171
3834Menarini18128
3927Bausch1620
4040Grifols1420
41N/AChugai943
42N/AIncyte772
4341Jazz Pharmaceuticals640
43N/AHorizon650
4550Shanghai400
4542Sun420
47N/APerrigo330
5042Jiangsu Hengrui000
5044CSPC000
5050Sino000

The latest insights from eHCPs mentioning the Top 50 Pharmaceutical Companies

The five pharmaceutical companies that were mentioned the most by eHCPs on Twitter in June 2023 were Pfizer, Moderna, Johnson & Johnson, AstraZeneca and Lilly.

CREATION.co identified 10,305 eHCP mentions of pharmaceutical companies in June 2023, decreasing by slightly over 10% from the previous month.

ASCO 2023, which was held from 02 – 06 June, affected eHCP conversation at the start of the month, with eHCPs sharing trial data, presentations and opinions on the latest updates in their online posts. Among the top shared posts from ASCO 2023 was a post by genitourinary oncologist, Dr Toni Choueiri – who shared a thread relating to phase 3 trial data for treatment for renal cell carcinoma.

Dr Choueiri concluded the thread by stating that no benefit was found in this trial. However, he commended Roche for their contributions towards this and other trials, and for their efforts in assessing the efficacy of this treatment against other cancers.

The next most shared post in the ASCO 2023 conversation was by Roger Olofsson Bagge, a professor in cancer surgery. He celebrated positive trial data for Moderna’s new mRNA cancer vaccine, highlighting his sentiments through emotive language on how the data was “so impressive that there is almost no need for phase III”. He was very pleased with the efforts by Moderna, and the important vaccine advancements made possible through mRNA technology.

Notably, HCPs also shared posts about pharma-HCP collaborations in health equity as seen in a post by Dr Estela Rodriguez, a thoracic oncologist. Dr Rodriguez shared a post demonstrating her collaboration with BMS in a workshop to address the disparities of trial inclusion, particularly with regard to Hispanic/Latino community members. 

Outside of the ASCO 2023 conversation, eHCPs engaged with data for Lilly’s new weight loss drug (retatrutide) – making Lilly this month’s fifth most mentioned company by HCPs online. eHCPs have reacted positively to retatrutide – with some eHCPs specifically highlighting data which demonstrated a significant 24% weight loss in 48 weeks.

The top shared links by eHCPs when mentioning a Top 50 pharma company discussed:

  1. An article discussing a report for inconsistencies in COVID vaccine studies
  2. An article referring to adverse events reported from vaccines.
  3. A roundtable discussion for patients who have been hospitalised by COVID-19 – supported by an educational grant from Gilead.

In June, the 2023 list of the Top 50 pharmaceutical companies by Pharm Exec was updated. The new companies joining this list include Perrigo, Chugai Pharmaceutical, Horizon Therapeutics, BioNTech, Incyte, and Novavax. 

BioNTech came into the list as the 11th most mentioned pharmaceutical company by eHCPs. This was due to eHCPs sharing the news about BioNTech initiating an application with the EU regulator for an updated COVID vaccine to target Omicron subvariant XBB.1.5, as seen in this post by physician Dr Hank Schiffers.

CREATION.co continues to analyse online eHCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology notes:

    • In June 2023, CREATION Pinpoint® identified 10,305  healthcare professional authored tweets from 4,351 individual eHCPs mentioning a Top 50 Pharmaceutical company (according to revenue). 
    • Data for this research was analysed from the online Twitter conversations of eHCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 June and 30 June 2023.
  • Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).
  • In some cases, a tweet may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
  • Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In June 2023, 89 of these posts mentioned Janssen.

Click here to read the latest Top 50 tracker

View all articles >

Meet the Author

Aman Jandu

With a background working in IT systems administration, and leveraging a 1st Class degree in Digital Technologies, Aman uses his technical skills to apply a systematic approach to gather data and analyse insights.

Aman loves to Speedcube. While he can currently solve a Rubik’s Cube in around 20 seconds, he is learning how to complete it blindfolded.

Suggested next


14.10.2020 | Case Study

Real-time tracking to understand & react to side effect discussion

Real-time tracking to understand & react to side effect discussion

Top 50 Pharma Tracker: HCPs mentioning Pharma in Relation to COVID-19

01.04.2020 | Article

Top 50 Pharma Tracker: HCPs mentioning Pharma in Relation to COVID-19

Top 50 Pharma Tracker: HCPs mentioning Pharma in Relation to COVID-19

By Mary Kangley

View all articles >